epidermal-growth-factor has been researched along with Protein-Losing-Enteropathies* in 2 studies
2 other study(ies) available for epidermal-growth-factor and Protein-Losing-Enteropathies
| Article | Year |
|---|---|
Anemia and hypogammaglobulinemia caused by Ménétrier's disease.
Topics: Adolescent; Agammaglobulinemia; alpha 1-Antitrypsin; Anemia; Biomarkers; Epidermal Growth Factor; Feces; Gastritis; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Protein-Losing Enteropathies; Tomography, Emission-Computed, Single-Photon | 2018 |
Octreotide reduces enteral protein losses in Ménétrier's disease.
A 47-yr-old man with Ménétrier's disease presented with profound enteral protein losses documented by 51Cr-albumin stool studies. There was no response to anticholinergics, H2-receptor antagonists, or proton pump inhibition. Subcutaneous octreotide acetate, 100 micrograms bid, resulted in clinical improvement with rapid resolution of enteral protein losses. Octreotide was continued for 12 months. During an additional 5-month follow-up period without therapy, the patient remained improved clinically with low to normal serum proteins, despite the persistence of gastric rugal hypertrophy. The evidence that octreotide resolved enteral protein losses and eliminated the need for urgent gastrectomy in our patient warrants a trial of this drug for other patients with Ménétrier's disease. Topics: Albumins; Chromium Radioisotopes; Epidermal Growth Factor; Feces; Gastric Acid; Gastrins; Gastritis, Hypertrophic; Humans; Injections, Subcutaneous; Male; Middle Aged; Octreotide; Protein-Losing Enteropathies; Saliva | 1993 |